A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
暂无分享,去创建一个
J. Schlom | S. Shen | W. Grizzle | E. Partridge | M. Barnes | R. Alvarez | R. Meredith | A. Lobuglio | W. Huh | L. Kilgore | M. Khazaeli | D. Carey | J. M. Austin | J. Austin
[1] L. Rubinstein,et al. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications. , 1991, International journal of radiation oncology, biology, physics.
[2] M. Mayo,et al. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] J. Schlom,et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.
[4] D. Snook,et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] F. Guadagni,et al. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Angioli,et al. Taxol sensitizes human ovarian cancer cells to radiation. , 1993, Gynecologic oncology.
[7] J. Schlom,et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] E. Padlan,et al. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. , 1999, Molecular immunology.
[9] E. Padlan,et al. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49. , 2001, Critical reviews in oncology/hematology.
[10] Elisa T. Lee,et al. Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.
[11] Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu‐CC49: A phase I/II study , 1997 .
[12] J. Murray,et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] J. Murray,et al. Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. , 1995, Cancer research.
[14] M. Khazaeli. Quantitation of mouse monoclonal antibody and human anti-mouse antibody response in serum of patients. , 1989, Hybridoma.
[15] J. Schlom,et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. , 2001, Cancer biotherapy & radiopharmaceuticals.
[16] W. Mason,et al. Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions. , 1990, The British journal of cancer. Supplement.
[17] A. Epenetos,et al. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.